http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4608495-B2

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
filingDate 2004-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2011-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2011-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-4608495-B2
titleOfInvention Triazole derivatives as factor Xa inhibitors
abstract The present invention relates to compounds of the formulae I and II, <CHEM> <CHEM> in which R<0>; R<1>; R<2>; R<3>; Q; J<1>; J<2>; J<3>; J<4>; J<5>; V; G and M have the meanings indicated in the claims. The compounds of the formulae I and II are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and II, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
priorityDate 2003-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81071
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35034
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35048
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35049
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35050
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00764
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35051
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP51588
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00775
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP24664
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP70059
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO97399
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP23916
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83348
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467096112
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19799
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID280686
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP84122
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00761
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP13726
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ59149

Total number of triples: 47.